Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: A randomized, placebo-controlled trial

Urology

Volumn 64, Issue 2, 2004, Pages 269-274

  Khullar, Vik ^a,g   Hill, Simon ^b   Laval, Karl Ulrich ^c   Schiøtz, Hjalmar A ^d   Jonas, Udo ^e   Versi, Eboo ^f  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY   (United Kingdom)

^c Urologist in Practice   (Germany)

^d VESTFOLD HOSPITAL TRUST   (Norway)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f Department of Pediatrics   (United States)

^g ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TOLTERODINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MICTURITION; MICTURITION DISORDER; NAUSEA; NEUROTOXICITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; STRESS INCONTINENCE; TREATMENT WITHDRAWAL; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINE RETENTION; URINE VOLUME; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 4143133420     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.02.029     Document Type: Article

References (25)

1. Thom D. Variation in estimates of urinary incontinence prevalence in the community effects of differences in definition, population characteristics and study type. J Am Geriatr Soc. 46:1998;473-480
2. Brown J.S., Grady D., Ouslander J.G., et al. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Obstet Gynecol. 94:1999;66-70
3. Hannestad Y.S., Rortveit G., Sandvik H., et al. A community-based epidemiological survey of female urinary incontinence the Norwegian EPINCONT study - Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol. 53:2000;1150-1157
4. Milsom I., Abrams P., Cardozo L., et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87:2001;760-766
5. Appell R.A. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder a pooled analysis. Urology. 50:(suppl 6A):1997;90-96
6. Abrams P., Freeman R., Anderstrom C., et al. Tolterodine, a new antimuscarinic agent as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol. 81:1998;801-810
7. Drutz H.P., Appell R.A., Gleason D., et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 10:1999;283-289
8. Malone-Lee J., Shaffu B., Anand C., et al. Tolterodine superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder. J Urol. 165:2001;1452-1456
9. Van Kerrebroeck P., Kreder K., Jonas U., et al. for the Tolterodine Study Group Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 57:2001;414-421
10. Hunskaar S., Vinsnes A. The quality of life in women with urinary incontinence as measured by the sickness impact profile. J Am Geriatr Soc. 39:1991;378-382
11. Van der Vaart C.H., De Leeuw J.R.J., Roovers J.P.W.R., et al. The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int. 90:2002;544-549
12. Kelleher C.J., Reese P.R., Pleil A.M., et al. Health-related quality of life of patients receiving extended release tolterodine for overactive bladder. Am J Manag Care. 8:(suppl):2002;S608-S615
13. Pleil A.M., Reese P.R., Kelleher C.J., et al. Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. Health Econ Prev Care (HEPAC). 2:2001;69-75
14. Coyne K., Matza L. Patient perception of bladder condition is a valid tool for evaluating the efficacy of overactive bladder therapy. Int Urogynecol J Pelvic Floor Dysfunct. 13:2002;S83
15. Kelleher C.J., Cardozo L.D., Khullar V., et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. 104:1997;1374-1379
16. Reese P.R., Pleil A.M., Okano G.J., et al. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res. 12:2003;427-442
17. Kelleher C.J., Pleil A.M., Okano G.J., et al. Long-term health-related quality of life of patients with overactive bladder receiving tolterodine. Neurourol Urodyn. 20:2001;505-506
18. Kobelt G., Kirchberger I., Malone-Lee J. Review quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int. 83:1999;583-590
19. Chakravarti IM, Laha RG, and Roy J: Handbook of Methods of Applied Statistics. New York, John Wiley & Sons, 1967, vol 1, pp 392-394
20. Abrams P, Wein A, Schussler B, et al. Recommendations of the International Scientific Committee: the evaluation and treatment of urinary incontinence, in Abrams P, Khoury S, Wein A (Eds): First International Consultation on Incontinence. Plymouth, UK, Health Publications, 1999, pp 945-975
21. Karram M.M., Bhatia N.N. Management of coexistent stress and urge urinary incontinence. Obstet Gynecol. 73:1989;4-7
22. Larsson G., Hallén B., Nilvebrant L. Tolterodine in the treatment of overactive bladder analysis of the pooled phase II efficacy and safety data. Urology. 53:1999;990-998
23. Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 6(11 suppl): S580-S590, 2000
24. Liberman J.N., Hunt T.L., Stewart W.F., et al. Health-related quality of life among adults with symptoms of overactive bladder results from a U.S. community-based survey. Urology. 57:2001;1044-1050
25. Weidner A.C. Which women with stress incontinence require urodynamic evaluation? Am J Obstet Gynecol. 184:2001;20-27